ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics Home
Connect with us
Call
Menu

Advanced diagnostic solutions to meet your unique needs

Healthcare Providers
BioPharma Leaders
Health Systems Executives

Experience the power of precision in every cancer diagnosis

Optimal outcomes in oncology start with excellent diagnostics, but they don't stop there. At Quest, we go beyond the test as your single-source solution, delivering reliable results, efficient processes, and world-class expertise across the cancer care continuum.

Hereditary genetic risk and colorectal cancer testing solutions

A comprehensive portfolio with testing from routine to advanced, including:

  • Colorectal cancer screening
  • Prostate cancer screening
  • Complete portfolio of hereditary cancer tests and services to support improved actionability, efficiency, and patient engagement

Subspecialized pathology solutions

Advanced pathology solutions that include:

  • 400+ subspecialized pathologists
  • Comprehensive bone marrow workup with integrated summary report
  • Digital pathology
  • Technical component (TC)/professional component (PC) and global solutions
  • Next-generation sequencing (NGS) for hematology

Molecular testing for evaluating prognosis:
  • MelaNodal Predict?
  • LeukoVantage??Myeloid Neoplasm Panels
  • Acute Myeloid Leukemia (AML) Rapid Mutation Panel
  • Prosigna??Breast Cancer Prognostic Gene Signature Assay

Precision medicine companion/complementary diagnosis, solid tumor NGS, heme NGS, hereditary cancer NGS

Solutions for solid tumor and hematologic malignancies:

  • Disease-specific panels
  • NCI trial matching
  • Pan-tumor biomarkers
  • NGS for solid tumors, hematology, and hereditary cancer
  • Comprehensive genomic profiling with 500+ genes: both RNA and DNA sequencing with over 50 gene fusions and copy number variants

Routine testing post treatment assessing therapy impact

High-precision minimal residual disease (MRD) testing:

  • Haystack MRD? for solid tumors
  • Heme MRD with molecular and flow cytometry solutions

Operationalize your precision oncology vision

Go beyond the test?with our unique offerings that include superlative logistics, with 4,500 courier vehicles and 20+ aircraft.
Start simplifying
QD-solid-tumor-solutions

Advancing the future of cancer care

Our commitment to progressive solutions means increased diagnostic accuracy, hundreds of routine and advanced tests, and dedication to better oncology care for your patients today¡ªand tomorrow.?And with Haystack MRD ?, you can identify residual, recurrent, or resistant cancer earlier than with traditional methods (eg, imaging or non-specific protein biomarkers).
Pathology solutions
QD-hem-cancer-solutions

Putting patients first

Making it easier for patients to access care is our priority. That's why we are in-network for most insurances nationwide, provide patient tools and services, and offer a range of financial support. Explore all the ways we help make care more accessible for patients.
Patient financial support
Oncology Putting Patients First

About our tests

Solid tumor
Hematology
Hereditary cancer risk
Skin cancer

? ?

Resources and insights

?

?

News & Trends
Publication
Cancer diagnoses still lag, 2 years into the pandemic
Pathology & Laboratory Medicine
Article
4 critical steps to optimize cancer diagnosis
Pathology & Laboratory Medicine
Article
Balancing the desire for quick AML results with precision genetic testing
Technology & Innovation
Article
The future of oncology diagnosis and patient care
Workforce Wellbeing
On-Demand Webinar
Early Detection Better Protection - Colorectal Cancer Screening in the Workplace: A Panel Discussion
View all resources

Contact us

Want to discover new ways oncology testing helps lead to better patient outcomes? Get in touch today.

784

* indicates required

Our company

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.